Combination HIV prevention during pregnancy and the post-partum period in Malawi and Zambia: a mathematical modelling analysis.
Africa
infectious disease transmission
perinatal care
prenatal care
sexual behaviour
sexual partners
Journal
Journal of the International AIDS Society
ISSN: 1758-2652
Titre abrégé: J Int AIDS Soc
Pays: Switzerland
ID NLM: 101478566
Informations de publication
Date de publication:
07 2023
07 2023
Historique:
received:
21
10
2022
accepted:
25
05
2023
medline:
6
7
2023
pubmed:
5
7
2023
entrez:
5
7
2023
Statut:
ppublish
Résumé
Despite widespread success in reducing vertical HIV transmission, most antenatal care (ANC) programmes in eastern and southern Africa have not emphasized primary prevention of maternal HIV acquisition during pregnancy and lactation/breastfeeding. We hypothesized that combination HIV prevention interventions initiated alongside ANC could substantially reduce maternal HIV incidence. We constructed a multi-state model describing male-to-female HIV transmission in steady heterosexual partnerships during pregnancy and lactation/breastfeeding, with initial conditions based on population distribution estimates for Malawi and Zambia in 2020. We modelled individual and joint increases in three HIV prevention strategies at or soon after ANC initiation: (1) HIV testing of male partners, resulting in HIV diagnosis and less condomless sex among those with previously undiagnosed HIV; (2) initiation (or re-initiation) of suppressive antiretroviral therapy (ART) for male partners with diagnosed but unsuppressed HIV; and (3) adherent pre-exposure prophylaxis (PrEP) for HIV-negative female ANC patients with HIV-diagnosed or unknown-status male partners. We estimated the percentage of within-couple, male-to-female HIV transmissions that could be averted during pregnancy and lactation/breastfeeding with these strategies, relative to base-case conditions in which 45% of undiagnosed male partners become newly HIV diagnosed via testing, 75% of male partners with diagnosed but unsuppressed HIV initiate/re-initiate ART and 0% of female ANC patients start PrEP. Increasing uptake of any single strategy by 20 percentage points above base-case levels averted 10%-11% of maternal HIV acquisitions during pregnancy and lactation/breastfeeding in the model. Joint uptake increases of 20 percentage points in two interventions averted an estimated 19%-23% of transmissions, and with a 20-percentage-point increase in uptake of all three interventions, 29% were averted. Strategies achieving 95% male testing, 90% male ART initiation/re-initiation and 40% female PrEP use reduced incident infections by 45%. Combination HIV prevention strategies provided alongside ANC and sustained through the post-partum period could substantially reduce maternal HIV incidence during pregnancy and lactation/breastfeeding in eastern and southern Africa.
Identifiants
pubmed: 37403422
doi: 10.1002/jia2.26128
pmc: PMC10320044
doi:
Substances chimiques
Anti-HIV Agents
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
e26128Subventions
Organisme : NIAID NIH HHS
ID : P30 AI050410
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI131060
Pays : United States
Organisme : NIMH NIH HHS
ID : P30 MH062294
Pays : United States
Organisme : FIC NIH HHS
ID : D43 TW010060
Pays : United States
Organisme : NIAID NIH HHS
ID : K24 AI120796
Pays : United States
Organisme : FIC NIH HHS
ID : D43 TW009340
Pays : United States
Informations de copyright
© 2023 The Authors. Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of the International AIDS Society.
Références
Glob Public Health. 2022 Aug-Sep;17(9):2081-2094
pubmed: 34375155
J Infect Dis. 2005 May 1;191(9):1403-9
pubmed: 15809897
J Infect Dis. 2018 Jun 5;218(1):16-25
pubmed: 29514254
J Acquir Immune Defic Syndr. 2005 Aug 1;39(4):446-53
pubmed: 16010168
Int J Gynaecol Obstet. 2012 Oct;119 Suppl 1:S26-9
pubmed: 22889550
Lancet Glob Health. 2021 Dec;9(12):e1719-e1729
pubmed: 34735862
HIV Clin Trials. 2017 May;18(3):100-109
pubmed: 28385131
N Engl J Med. 2011 Aug 11;365(6):493-505
pubmed: 21767103
Curr HIV/AIDS Rep. 2021 Feb;18(1):73-86
pubmed: 33400169
Bull World Health Organ. 2018 Jan 1;96(1):69-71
pubmed: 29403103
AIDS. 2022 Jan 1;36(1):39-48
pubmed: 34534138
Lancet Infect Dis. 2008 Sep;8(9):553-63
pubmed: 18684670
J Acquir Immune Defic Syndr. 2017 Nov 1;76(3):259-265
pubmed: 28777265
AIDS. 2019 Jul 1;33(8):1391-1395
pubmed: 30950882
J Stat Softw. 2015 Mar;64(10):1-22
pubmed: 26064082
Lancet HIV. 2020 Jan;7(1):e38-e48
pubmed: 31813837
BMJ Open. 2021 Jun 30;11(6):e046032
pubmed: 34193491
J Int AIDS Soc. 2019 Jul;22 Suppl 3:e25293
pubmed: 31321884
Int Health. 2020 Sep 1;12(5):484-498
pubmed: 31613327
Trop Med Infect Dis. 2022 Jul 29;7(8):
pubmed: 36006246
PLoS One. 2020 Nov 9;15(11):e0242001
pubmed: 33166351
PLoS One. 2019 Oct 4;14(10):e0223487
pubmed: 31584987
N Engl J Med. 2012 Aug 2;367(5):399-410
pubmed: 22784037
AIDS. 2020 Apr 1;34(5):761-776
pubmed: 32167990
AIDS Care. 2008 Sep;20(8):958-68
pubmed: 18608073
BMC Infect Dis. 2022 Feb 8;22(1):134
pubmed: 35135474